- GLP-1 peptides are prescription-only injectable medicines in the United States — there is no lawful over-the-counter or consumer-direct channel.
- Semaglutide is a GLP-1 receptor agonist; tirzepatide is a dual GIP and GLP-1 receptor agonist. They are related but pharmacologically distinct.
- FDA declared the tirzepatide shortage resolved in December 2024 and the semaglutide shortage resolved in February 2025, which removed the legal basis for compounding essential copies.
- Per FDA labelling, subcutaneous semaglutide is administered once weekly into the abdomen, thigh, or upper arm, with site rotation.
- Licensed clinics and pharmacies should source GLP-1 injectables only through state-licensed, DSCSA-compliant distributors.
GLP-1 receptor agonists havemoved from a niche diabetes category to one of the most significant therapeuticclasses in modern medicine. For pharmacies, clinics, and healthcare facilities,that shift has created a sourcing environment that is commercially attractiveand regulatorily hazardous in equal measure.
This article explains what GLP-1peptides are, how the major molecules differ, what changed after the FDAresolved the semaglutide and tirzepatide shortages, and what licensed buyersshould verify before purchasing.
Glucagon-like peptide-1 (GLP-1)is an incretin hormone released by the intestine in response to food intake. Itstimulates glucose-dependent insulin secretion, suppresses glucagon release,slows gastric emptying, and acts on central appetite pathways.
Native GLP-1 is degraded withinminutes by the enzyme DPP-4, which makes it useless as a therapy in its naturalform. GLP-1 peptides — the therapeutic analogues — are engineered to resistthat degradation and remain active for days rather than minutes. This is whatallows a once-weekly GLP-1 injectable to exist at all.
Because these molecules arepeptide chains rather than small molecules, they carry the handlingcharacteristics of biologics: temperature sensitivity, susceptibility toagitation and light, and a genuine need for validated cold chain distribution.
Semaglutide is a GLP-1 receptoragonist developed by Novo Nordisk. In the United States it is approved underseveral brand names with distinct indications.
• Ozempic— subcutaneous semaglutide indicated for type 2 diabetes mellitus, withadditional cardiovascular and renal indications added over time.
• Wegovy— subcutaneous semaglutide at higher dosing, indicated for chronic weightmanagement in eligible patients.
• Rybelsus— an oral tablet formulation of semaglutide for type 2 diabetes.
These are not interchangeableproducts. They differ in approved indication, titration schedule, and dosing.Substituting one for another is a prescribing decision, not a procurement one.
FDA-approved labelling forsubcutaneous semaglutide specifies administration into the abdomen, thigh, orupper arm, once weekly, on the same day each week. Labelling directs thatinjection sites be rotated with each dose.
This is standard information fordispensing pharmacists and prescribers to reference when counselling patients,and it should always be taken from the current approved labelling for thespecific product being dispensed rather than from secondary sources.Administration guidance is a clinical matter for the treating prescriber anddispensing pharmacist — a distributor's role is to ensure the product arrivesintact, in-date, and fully documented.
Semaglutide products requirerefrigerated storage within the range specified in the product labelling, withdefined limits on in-use storage at room temperature once a pen is first used.Buyers should confirm that their distributor ships in validated, temperature-monitoredpackaging and has a documented procedure for handling and reporting excursions.
Tirzepatide, developed by EliLilly, is frequently grouped with GLP-1 peptides, but it is mechanisticallydistinct. It is a dual agonist, acting at both the glucose-dependentinsulinotropic polypeptide (GIP) receptor and the GLP-1 receptor.
In the United States,tirzepatide is approved as Mounjaro for type 2 diabetes and as Zepbound forchronic weight management and, subsequently, for moderate-to-severe obstructivesleep apnoea in adults with obesity.
Head-to-head clinical evidencehas generally shown greater average weight reduction with tirzepatide than withsemaglutide, though individual response, tolerability, indication, and payercoverage all bear on clinical selection. Referring to these products as"tirzepatide peptides" or "weight loss peptides" is commonin commercial shorthand, but the clinical reality is that they are preciselyindicated prescription medicines with defined patient populations andmonitoring requirements.
This is the most consequentialrecent development for anyone sourcing GLP-1 products, and it is still widelymisunderstood.
During the extended shortages ofsemaglutide and tirzepatide, both molecules appeared on the FDA drug shortagelist. Under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act,compounding pharmacies and outsourcing facilities are generally prohibited fromproducing what is essentially a copy of a commercially available approved drug— but a shortage listing creates an exception. That exception is what enabledthe very large compounded GLP-1 market that developed from 2023 onward.
FDA declared the tirzepatideshortage resolved in December 2024 and the semaglutide shortage resolved inFebruary 2025. With the shortages resolved, the exception fell away, and FDAset wind-down dates in the spring of 2025 after which compounding essentialcopies was no longer permissible.
The practical implications forbuyers are direct.
1. Thecompliant route for these molecules is FDA-approved product, sourced throughthe licensed distribution chain.
2. Offersof bulk "compounded semaglutide" or "compoundedtirzepatide" as routine stock should be treated as a serious complianceconcern.
3. Sellersmarketing these molecules as "research peptides" to clinics areoperating outside the approved drug framework entirely.
4. Personalisedcompounding for an individual patient with a documented clinical need is anarrow and fact-specific question that belongs with your regulatory counsel andstate board — not with a supplier's sales team.
Regulatory positions in thisarea have moved quickly and continue to be litigated. Verify the current statusbefore relying on any of it operationally.
For a licensed pharmacy, clinic,or healthcare facility, the sourcing standard is straightforward even if themarket is noisy. Purchase FDA-approved GLP-1 injectable products from awholesale distributor that is licensed in your state, registered with FDA, anddemonstrably DSCSA-compliant.
Before placing an order, confirmthe following.
• Thedistributor holds current wholesale drug distributor licensure in yourdestination state, not only in its own.
• Productis FDA-approved, in original manufacturer packaging, with intact serialisation.
• FullDSCSA transaction information is provided electronically with every shipment.
• Coldchain is validated and temperature-monitored, with a written excursionprocedure.
• Datingis acceptable and disclosed before purchase, not on arrival.
• Thedistributor can trace lots for recall purposes and will notify you directly.
• Pricingis explicable. GLP-1 products offered far below market carry a meaningfulprobability of being diverted, counterfeit, or not what the label claims.
Counterfeit GLP-1 products havebeen documented in the US supply chain, including counterfeit pens that reachedpatients. Purchasing outside the licensed distribution chain is the primary waycounterfeits enter a practice.
If a state board inspector, anFDA investigator, or a manufacturer's diversion team asks how a specific vialreached your practice, you should be able to answer within minutes. Build therecord at the point of receipt rather than reconstructing it under pressure.
Retain the following for eachGLP-1 injectable shipment you accept.
• TheDSCSA transaction information and transaction statement supplied by thedistributor.
• Thepurchase order, invoice, and packing list, reconciled against what physicallyarrived.
• Lotnumbers, expiry dates, and serialisation identifiers for the units received.
• Temperaturemonitoring data or indicator readings from the shipment, plus any excursioninvestigation.
• Adated receiving record noting the condition of the packaging on arrival and thename of the person who checked it in.
• Copiesof the distributor's current licensure, refreshed annually rather than filedonce and forgotten.
This documentation also protectsyou commercially. If a product is later recalled or found to be counterfeit, acomplete receiving record is what separates a contained, evidenced responsefrom an open-ended investigation into your entire inventory.
No. Semaglutide and tirzepatideproducts are prescription-only medicines. Any channel offering them forconsumer purchase without a prescription is operating unlawfully, and theproduct's provenance cannot be assured.
Semaglutide is a single-targetGLP-1 receptor agonist. Tirzepatide is a dual agonist acting at both GIP andGLP-1 receptors. They have different approved indications, dosing schedules,and clinical trial evidence, and the choice between them is a prescribingdecision.
Following FDA's resolution ofboth shortages and the subsequent wind-down dates in 2025, the exception thatpermitted compounding essential copies of these drugs no longer applies. Narrowclinical circumstances may exist, but they are fact-specific and should beassessed with regulatory counsel and the relevant state board.
Approved labelling forsubcutaneous semaglutide specifies the abdomen, thigh, or upper arm, onceweekly, with rotation of injection sites. Patients should follow theinstructions provided by their prescriber and the current product labelling.
Refrigerated within the rangestated in the approved labelling, protected from light, not frozen, withmonitored refrigeration and documented temperature logs. In-use roomtemperature limits apply once a pen is first used and vary by product.
The GLP-1 category is unusuallyattractive to bad actors: high demand, high value, high patient motivation.That combination has produced a large grey market operating alongside thelegitimate supply chain, often using near-identical language.
For a licensed buyer, theprotective measures are unglamorous and effective. Buy FDA-approved product.Buy from a state-licensed, DSCSA-compliant distributor. Insist on fulltransaction documentation and validated cold chain. Treat unexplained discountsas a warning rather than an opportunity.
BIGG Pharma Wholesale is alicensed B2B pharmaceutical wholesale distributor based in Plano, Texas,supplying licensed pharmacies, clinics, and healthcare facilities. We providefull transaction documentation, verified sourcing, and validated handling onevery order.
Speak to our team about yourrequirements:
Aaron | BIGGPharma Wholesale
Email: Aaron@biggpharmawholesale.com
Phone: +1 (781) 996-9405
Licence verification is required before any order is processed.
Disclaimer: This article isintended for licensed healthcare professionals, pharmacies, and institutionalbuyers. It is provided for general informational purposes only and does notconstitute medical, legal, or regulatory advice. It is not intended for patientsor consumers and does not promote or recommend any product for personal use.Regulatory requirements change; verify current federal and state requirementswith the FDA, DEA, and your state board before acting on any information here.Prescription medicines require a valid prescription issued by a licensedpractitioner.